Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EBITDA (2016 - 2025)

Voyager Therapeutics' EBITDA history spans 11 years, with the latest figure at -$27.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 21.4% year-over-year to -$27.4 million; the TTM value through Dec 2025 reached -$119.3 million, down 82.5%, while the annual FY2025 figure was -$119.3 million, 82.5% down from the prior year.
  • EBITDA for Q4 2025 was -$27.4 million at Voyager Therapeutics, up from -$27.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $124.1 million in Q1 2023 and bottomed at -$34.9 million in Q4 2024.
  • The 5-year median for EBITDA is -$21.9 million (2021), against an average of -$8.5 million.
  • The largest annual shift saw EBITDA crashed 512.49% in 2022 before it skyrocketed 679.94% in 2023.
  • A 5-year view of EBITDA shows it stood at $5.7 million in 2021, then plummeted by 512.49% to -$23.5 million in 2022, then surged by 340.75% to $56.6 million in 2023, then plummeted by 161.6% to -$34.9 million in 2024, then increased by 21.4% to -$27.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's EBITDA are -$27.4 million (Q4 2025), -$27.7 million (Q3 2025), and -$33.4 million (Q2 2025).